Last Updated: November 16, 2026

GANAXOLONE - Generic Drug Details

« Back to Dashboard


What are the generic sources for ganaxolone and what is the scope of patent protection?

Ganaxolone is the generic ingredient in one branded drug marketed by Immedica Pharma and is included in one NDA. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for GANAXOLONE
International Patents:50
US Patents:11
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 46
Clinical Trials: 24
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for GANAXOLONE
What excipients (inactive ingredients) are in GANAXOLONE?GANAXOLONE excipients list
DailyMed Link:GANAXOLONE at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for GANAXOLONE
Generic Entry Date for GANAXOLONE*:
Constraining patent/regulatory exclusivity:
Dosage:

SUSPENSION;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for GANAXOLONE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Massachusetts General HospitalN/A
Marinus PharmaceuticalsPhase 3
National Institute on Drug Abuse (NIDA)Phase 2

See all GANAXOLONE clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for GANAXOLONE

US Patents and Regulatory Information for GANAXOLONE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Immedica Pharma ZTALMY ganaxolone SUSPENSION;ORAL 215904-001 Jun 1, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Immedica Pharma ZTALMY ganaxolone SUSPENSION;ORAL 215904-001 Jun 1, 2022 RX Yes Yes 8,022,054 ⤷  Start Trial Y ⤷  Start Trial
Immedica Pharma ZTALMY ganaxolone SUSPENSION;ORAL 215904-001 Jun 1, 2022 RX Yes Yes 12,115,169 ⤷  Start Trial ⤷  Start Trial
Immedica Pharma ZTALMY ganaxolone SUSPENSION;ORAL 215904-001 Jun 1, 2022 RX Yes Yes 8,318,714 ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for GANAXOLONE

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Marinus Pharmaceuticals Emerald Limited Ztalmy ganaxolone EMEA/H/C/005825Ztalmy is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 to 17 years of age. Ztalmy may be continued in patients 18 years of age and older. Authorised no no yes 2023-07-26
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Supplementary Protection Certificates for GANAXOLONE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1959966 C202430002 Spain ⤷  Start Trial PRODUCT NAME: GANAXOLONA; NATIONAL AUTHORISATION NUMBER: EU/1/23/1743; DATE OF AUTHORISATION: 20230726; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/23/1743; DATE OF FIRST AUTHORISATION IN EEA: 20230726
1959966 122024000005 Germany ⤷  Start Trial PRODUCT NAME: GANAXOLON; REGISTRATION NO/DATE: EU/1/23/1743 20230726
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Ganaxolone Market Dynamics, Revenue Trajectory, Patent Protection, and Commercial Outlook

Last updated: September 21, 2026

Ganaxolone is a differentiated neuroactive steroid marketed by Marinus Pharmaceuticals as Ztalmy. The FDA approved Ztalmy in March 2022 for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder, or CDKL5 deficiency disorder, in patients aged 2 years and older. The commercial opportunity is concentrated in a small ultra-rare population, while the larger valuation case depends on expansion into tuberous sclerosis complex and status epilepticus.

Ztalmy generated approximately $22 million in product revenue in 2023, up sharply from its launch-year performance. Publicly reported 2024 results showed continued quarterly growth, but the product remained unprofitable because of high selling, medical-affairs, clinical-development, and manufacturing costs. The main commercial risks are limited diagnosed prevalence, payer friction, reliance on one product, and setbacks in broader epilepsy indications.

What is ganaxolone and how is Ztalmy used?

Ganaxolone is a synthetic analog of the endogenous neurosteroid allopregnanolone. It modulates synaptic and extrasynaptic GABA-A receptors, including receptors containing delta subunits. Ztalmy is supplied as an oral suspension and is administered three times daily with food.

Product Active ingredient FDA indication Dosage form Sponsor
Ztalmy Ganaxolone Seizures associated with CDKL5 deficiency disorder Oral suspension Marinus Pharmaceuticals
Zulresso Brexanolone Postpartum depression Intravenous infusion Sage Therapeutics

Ganaxolone and brexanolone are pharmacologically related neuroactive steroids, but they are separate products with different indications, delivery systems, commercial markets, and patent estates.

The CDKL5 indication is a rare-disease market. CDKL5 deficiency disorder is a severe developmental and epileptic encephalopathy that generally begins in infancy or early childhood. Patients often require several antiseizure medicines, creating a commercial rationale for adjunctive treatment. The small patient population limits volume but supports orphan-drug pricing and specialist distribution.

When did Ztalmy receive FDA approval and orphan exclusivity?

The FDA approved Ztalmy on March 18, 2022, for patients at least 2 years old with seizures associated with CDKL5 deficiency disorder. The approval was based principally on a randomized, double-blind clinical trial evaluating reduction in 28-day major motor seizure frequency. The FDA granted orphan-drug designation, giving Ztalmy seven years of orphan-drug exclusivity for the approved indication under the Orphan Drug Act (FDA, 2022a).

Milestone Date or status
FDA approval March 18, 2022
Orphan-drug exclusivity Expected through March 18, 2029
Initial approved population Patients aged 2 years and older
Regulatory pathway New drug application
Product type Small-molecule oral suspension
Pediatric exclusivity No separate six-month pediatric extension is included in the core approval date above

Orphan-drug exclusivity does not prevent every competing product from entering the market. A competitor may challenge exclusivity by showing clinical superiority, or may pursue a different indication. Patent protection, FDA exclusivity, and market access therefore operate as separate barriers.

How has ganaxolone revenue developed?

Ztalmy’s revenue ramp has been gradual rather than rapid. The launch benefited from an established specialty-pharmacy model and a concentrated prescriber base, but the addressable population is limited.

Period Commercial development Approximate reported product revenue
2022 Initial commercial launch About $4 million to $5 million
2023 Broader patient identification and payer coverage About $22 million
2024 Continued quarterly growth and higher treated-patient penetration Approximately $30 million range based on company-reported quarterly performance
2025 onward Dependent on CDKL5 growth, TSC development, and corporate financing Highly dependent on regulatory and financing outcomes

Marinus reported approximately $21.7 million of Ztalmy net product revenue in 2023, compared with approximately $4.5 million in 2022. Revenue growth reflected increased prescriptions, patient starts, and commercial execution rather than a major expansion of the approved label (Marinus Pharmaceuticals, 2024a).

The revenue base remains small relative to the cost of a specialty pharmaceutical organization. Marinus has needed to fund:

  • Commercial and patient-support infrastructure.
  • Medical education in a rare pediatric epilepsy population.
  • Clinical trials in larger indications.
  • Manufacturing and supply-chain activities for an oral suspension.
  • Regulatory and postmarketing obligations.

The key financial question is whether Ztalmy can reach sufficient scale before cash consumption forces additional financing, asset monetization, licensing, or restructuring.

What is the market opportunity for ganaxolone in CDKL5 deficiency disorder?

The CDKL5 market is commercially attractive per patient but limited in absolute volume. The disorder is rare, underdiagnosed, and geographically uneven. Treatment is concentrated in pediatric neurologists, epilepsy centers, and specialty pharmacies.

CDKL5 commercial drivers

The main demand drivers are:

  1. High seizure burden and substantial unmet need.
  2. Chronic treatment duration.
  3. A limited number of approved therapies specifically positioned for CDKL5 deficiency disorder.
  4. Orphan-drug reimbursement mechanisms.
  5. Potential for improved diagnosis through genetic testing.

The main constraints are:

  • Small diagnosed population.
  • Variable payer requirements for genetic confirmation.
  • Prior authorization and step-therapy requirements.
  • Caregiver complexity associated with a three-times-daily suspension.
  • Potential discontinuation from adverse events, inadequate seizure response, or administration burden.
  • Dependence on a rare-disease sales force rather than broad primary-care prescribing.

Ztalmy’s commercial ceiling in CDKL5 alone is therefore constrained. Sustained value creation requires either higher penetration, label expansion, international commercialization, or a partner with a broader epilepsy infrastructure.

Which clinical indications could expand the ganaxolone market?

Marinus has pursued ganaxolone in tuberous sclerosis complex, or TSC, and status epilepticus. These indications have materially larger patient pools than CDKL5 deficiency disorder.

Tuberous sclerosis complex

TSC is a genetic disorder associated with epilepsy, developmental impairment, and benign tumors in multiple organs. Seizures affect a large proportion of patients, and a meaningful subset has drug-resistant epilepsy.

Ganaxolone’s TSC opportunity is commercially relevant because:

  • The population is larger than the CDKL5 population.
  • Treatment may begin earlier and continue chronically.
  • TSC has established specialist treatment pathways.
  • The market already includes branded and generic antiseizure drugs, creating competition but also validated demand.

The principal issue is clinical differentiation. Ganaxolone must demonstrate a meaningful seizure-reduction benefit against established therapies, including vigabatrin, everolimus, cannabidiol, and standard antiseizure medicines. A successful TSC approval could materially increase peak-sales potential. A failed or delayed trial would leave Marinus dependent on the narrow CDKL5 market.

Status epilepticus

Status epilepticus is an acute hospital setting in which seizures require rapid treatment. Ganaxolone has been studied as an intravenous and oral-treatment candidate for patients whose seizures persist after initial therapy.

The status epilepticus market is larger in patient volume but more difficult commercially. Product adoption depends on:

  • Demonstrated reduction in treatment failure.
  • Rapid onset of action.
  • Hospital formulary placement.
  • Comparative safety against benzodiazepines, anesthetics, and other rescue medicines.
  • Reimbursement under hospital payment systems.
  • Manufacturing capacity for acute-care presentations.

The RAISE clinical program did not deliver the expected regulatory pathway during the period covered by Marinus’ public filings. That setback weakened the near-term expansion case and increased reliance on Ztalmy revenue from CDKL5 and any future TSC approval (Marinus Pharmaceuticals, 2024b).

What patents protect ganaxolone and Ztalmy?

Ganaxolone has a layered intellectual-property position involving the active molecule, pharmaceutical formulations, methods of treatment, and potentially specific clinical uses. The commercial protection profile is more complex than the basic compound patent because ganaxolone was discovered and studied before Ztalmy’s approval.

Protection category Commercial relevance
Compound patents Protect ganaxolone chemistry where unexpired claims remain
Formulation patents May cover oral suspension composition, particle characteristics, excipients, or stability
Method-of-use patents May cover treatment of CDKL5 deficiency disorder, TSC, or other seizure conditions
Manufacturing patents May restrict specific production or purification processes
FDA orphan exclusivity Protects the approved CDKL5 indication through approximately March 2029
Pediatric exclusivity Depends on a separate FDA grant and is not assumed in the base timeline

The most important practical protection is the combination of orphan exclusivity, formulation know-how, clinical data, and prescriber adoption. Ganaxolone’s underlying molecule is older than Ztalmy’s approval, so the durability of the estate depends heavily on later-issued formulation and method-of-use claims.

The FDA Orange Book is the controlling public source for patents listed against the approved Ztalmy product. Patent expiry dates can differ by patent, terminal disclaimer, patent-term adjustment, and pediatric extension. A generic applicant would need to assess each listed claim rather than rely on a single headline expiry date.

When does ganaxolone lose exclusivity?

The first major regulatory exclusivity event is the expected expiration of orphan-drug exclusivity in March 2029. This does not necessarily mark the earliest possible generic entry because patent litigation, FDA review timing, and formulation patents may extend commercial protection.

Generic entry scenarios

Scenario Likely commercial effect
No Paragraph IV challenge before 2029 Ztalmy retains a stronger position until patent and regulatory barriers fall
Paragraph IV challenge to listed patents Marinus may face Hatch-Waxman litigation and a potential 30-month stay
Successful patent challenge Earlier generic entry becomes possible, subject to FDA approval
Generic approval after orphan exclusivity Price pressure and payer substitution could develop quickly
Competing product for a different indication May enter without directly violating CDKL5 orphan exclusivity

A generic version of the same oral suspension could face technical and regulatory issues involving bioequivalence, active-ingredient uniformity, dosing devices, palatability, and manufacturing consistency. Those barriers are meaningful but generally less durable than patents or orphan exclusivity.

What is the Paragraph IV and litigation risk for Ztalmy?

No major public Paragraph IV challenge to Ztalmy had become a central commercial event in the company’s reported filings through the available period. The absence of a disclosed challenge does not eliminate future risk. The probability of litigation increases as the orphan-exclusivity and patent-expiry windows approach.

Potential litigation issues include:

  • Validity of formulation claims.
  • Obviousness of oral ganaxolone formulations.
  • Written-description and enablement requirements for broad method-of-use claims.
  • Patent-term calculations.
  • Whether a generic product infringes use-specific claims.
  • Whether the proposed label omits protected indications.

The litigation risk is lower in the near term than for a large primary-care product because the CDKL5 market is small. A generic challenger must justify the cost of litigation against a limited revenue opportunity.

How strong is the ganaxolone patent estate?

Ganaxolone has a moderate commercial protection profile rather than an exceptionally long or broad one.

Strengths

  • FDA orphan exclusivity for the approved CDKL5 indication.
  • Specialist prescriber concentration.
  • Clinical and manufacturing know-how.
  • Potential formulation barriers for an oral suspension.
  • Opportunity to obtain additional method-of-use claims from later approvals.

Weaknesses

  • The active compound is not newly discovered.
  • The CDKL5 population is small, limiting litigation economics.
  • Method-of-use claims may be narrower than composition claims.
  • Future indications could invite separate competition.
  • A generic could target an unprotected indication or rely on a carve-out label.

The value of the patent estate is therefore tied to commercial execution and indication expansion. Patents alone are unlikely to support a large valuation if Ztalmy remains limited to CDKL5 deficiency disorder.

How does ganaxolone compare with competing epilepsy drugs?

Product Company Key epilepsy use Commercial position
Ztalmy Marinus CDKL5 deficiency disorder Targeted orphan product
Fintepla Jazz Pharmaceuticals Dravet syndrome and Lennox-Gastaut syndrome Larger rare-epilepsy franchise
Epidiolex Jazz Pharmaceuticals Dravet syndrome, Lennox-Gastaut syndrome, TSC Broad approved rare-epilepsy platform
Sabril Lundbeck and generics Infantile spasms and TSC-related use Established, with generic pressure
Everolimus Novartis and generics TSC-associated seizures Disease-modifying TSC platform
Standard antiseizure medicines Multiple companies Broad epilepsy use Low-cost and entrenched alternatives

Ganaxolone’s differentiation is its neurosteroid mechanism and CDKL5-specific approval. Its disadvantage is the absence, so far, of a broad epilepsy label comparable with cannabidiol or everolimus.

What is the FDA and regulatory outlook for ganaxolone?

The regulatory outlook has two parts:

  1. Defend and grow the approved Ztalmy franchise.
  2. Obtain a second indication that expands the addressable market.

The CDKL5 approval provides regulatory validation, but the product’s long-term value depends on a larger indication. TSC is the clearest commercial expansion opportunity. Status epilepticus offers a larger theoretical market but carries higher development and adoption risk.

For investors and potential partners, the key milestones are:

  • Additional FDA approvals.
  • Label expansion into TSC.
  • Evidence of durable prescribing in CDKL5.
  • Evidence that payer coverage improves with post-launch experience.
  • Resolution of manufacturing and supply requirements.
  • Patent listings and challenge activity approaching 2029.

What revenue exposure and commercial risks does Marinus face?

Marinus is highly exposed to ganaxolone because Ztalmy is its principal commercial product. This concentration creates operating leverage if sales grow, but it also increases downside risk from clinical setbacks, reimbursement restrictions, or financing pressure.

Risk Financial consequence
CDKL5 market remains small Revenue ceiling remains limited
Slow patient identification Delayed prescription growth
Payer restrictions Lower starts and longer time to treatment
Failed TSC development Reduced peak-sales expectations
Status epilepticus setback Loss of a major expansion path
Generic or follow-on competition Price erosion after exclusivity
Manufacturing interruption Product shortages and lost prescriptions
High operating expense Continued cash burn despite revenue growth

The commercial model can reach sustainability only if revenue growth outpaces the cost of clinical development and specialty commercialization. A TSC approval would materially improve that equation. Without it, Marinus would remain dependent on a narrow orphan indication and external capital.

Key Takeaways

  • Ganaxolone is marketed as Ztalmy for CDKL5 deficiency disorder in patients aged 2 years and older.
  • FDA approval occurred on March 18, 2022, with orphan-drug exclusivity expected through March 18, 2029.
  • Product revenue increased from approximately $4 million to $5 million in 2022 to approximately $22 million in 2023.
  • 2024 revenue was tracking in the approximately $30 million range based on reported quarterly performance.
  • CDKL5 provides a defensible specialty market but is too small by itself to support a large commercial platform.
  • TSC is the most important potential expansion indication.
  • Status epilepticus represents a larger opportunity but carries greater clinical, regulatory, and hospital-adoption risk.
  • The patent estate likely depends more on formulation and method-of-use protection than on a long-lived basic compound patent.
  • No major publicly disclosed Paragraph IV challenge had become a central commercial event through the available reporting period.
  • Marinus remains highly exposed to ganaxolone revenue, clinical-development outcomes, and financing requirements.

FAQs About Ganaxolone Market Potential and Exclusivity

Is ganaxolone a generic drug?

No. Ztalmy is a branded prescription product marketed by Marinus Pharmaceuticals. Generic ganaxolone entry would require an FDA-approved abbreviated new drug application and resolution of applicable patent and exclusivity barriers.

Is Ztalmy approved for tuberous sclerosis complex?

The FDA approval discussed here is for seizures associated with CDKL5 deficiency disorder. TSC expansion depends on clinical and regulatory outcomes separate from the original approval.

Does ganaxolone compete with Epidiolex?

Yes. The products can compete in rare epilepsy markets, particularly where physicians and payers consider Epidiolex, ganaxolone, everolimus, and established antiseizure medicines for patients with difficult-to-control seizures.

What is the biggest commercial risk for Ztalmy?

The largest risk is that the product remains confined to a small CDKL5 population without a successful expansion into TSC or another larger indication.

Could a generic launch before 2029?

A direct generic launch before the expected end of orphan exclusivity would face substantial regulatory barriers. Earlier entry could occur only through a legally viable alternative, such as a different indication, a successful patent challenge, or a product not blocked by the applicable exclusivity protections.

References

  1. U.S. Food and Drug Administration. (2022a). FDA approves first treatment for seizures associated with CDKL5 deficiency disorder. https://www.fda.gov/

  2. U.S. Food and Drug Administration. (2022b). Ztalmy prescribing information. Marinus Pharmaceuticals, Inc. https://www.accessdata.fda.gov/

  3. Marinus Pharmaceuticals, Inc. (2024a). Annual report on Form 10-K for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission. https://www.sec.gov/

  4. Marinus Pharmaceuticals, Inc. (2024b). Quarterly reports and investor disclosures regarding ganaxolone clinical development and commercial revenue. U.S. Securities and Exchange Commission. https://www.sec.gov/

  5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/giindex.cfm

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.